Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8732699rdf:typepubmed:Citationlld:pubmed
pubmed-article:8732699lifeskim:mentionsumls-concept:C0024109lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0597032lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0206180lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0599733lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0431085lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0013142lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0544452lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0035007lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0205092lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0231242lld:lifeskim
pubmed-article:8732699lifeskim:mentionsumls-concept:C0205221lld:lifeskim
pubmed-article:8732699pubmed:issue2lld:pubmed
pubmed-article:8732699pubmed:dateCreated1997-1-14lld:pubmed
pubmed-article:8732699pubmed:abstractTextWe report on the immuno-oncologic analysis and treatment of a remarkable case of disseminated CD30+ anaplastic non-Hodgkin's lymphoma. Its clinical course was characterized by repeated spontaneous regressions, which were probably due to a T-cell-mediated anti-lymphoma immune reaction, as tumor-infiltrating T lymphocytes were consistently observed in sections of lymphoma lesions and found to express high-affinity receptors for interleukin-2 (IL-2). This marker may be particularly suitable to predict a response to low-dose recombinant IL-2 (rIL-2), as confirmed in this case by prompt lymphoma regression after regional rIL-2 perfusion of a cutaneous lesion and by an impressive overall response to systemic rIL-2 treatment. Despite the very low dose of rIL-2, 600,000 IU/24 h as a continuous i.v. infusion, systemic treatment was complicated by generalized capillary leakage and life-threatening unilateral drowning of the lymphoma-infiltrated left lung.lld:pubmed
pubmed-article:8732699pubmed:languageenglld:pubmed
pubmed-article:8732699pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8732699pubmed:citationSubsetIMlld:pubmed
pubmed-article:8732699pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8732699pubmed:statusMEDLINElld:pubmed
pubmed-article:8732699pubmed:monthMarlld:pubmed
pubmed-article:8732699pubmed:issn1067-5582lld:pubmed
pubmed-article:8732699pubmed:authorpubmed-author:BoyMMlld:pubmed
pubmed-article:8732699pubmed:authorpubmed-author:van't VeerM...lld:pubmed
pubmed-article:8732699pubmed:authorpubmed-author:SlingerlandRRlld:pubmed
pubmed-article:8732699pubmed:authorpubmed-author:VlasveldL TLTlld:pubmed
pubmed-article:8732699pubmed:authorpubmed-author:GratamaJ WJWlld:pubmed
pubmed-article:8732699pubmed:authorpubmed-author:BeunG DGDlld:pubmed
pubmed-article:8732699pubmed:issnTypePrintlld:pubmed
pubmed-article:8732699pubmed:volume19lld:pubmed
pubmed-article:8732699pubmed:ownerNLMlld:pubmed
pubmed-article:8732699pubmed:authorsCompleteYlld:pubmed
pubmed-article:8732699pubmed:pagination162-7lld:pubmed
pubmed-article:8732699pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:meshHeadingpubmed-meshheading:8732699-...lld:pubmed
pubmed-article:8732699pubmed:year1996lld:pubmed
pubmed-article:8732699pubmed:articleTitleLow-dose rIL-2-induced remission of disseminated CD30+ anaplastic large-cell lymphoma through reinforcement of presumed T-cell-mediated tumor cell killing, complicated by unilateral drowning of lymphoma-infiltrated lung.lld:pubmed
pubmed-article:8732699pubmed:affiliationDepartment of Hematology, Dr. Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.lld:pubmed
pubmed-article:8732699pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8732699pubmed:publicationTypeCase Reportslld:pubmed